Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metivi
- Development stage
- Preclinical
- Lead developer
- Esperante Development
- Administration
- Ophthalmic
01
Overview
Metivi (also known as DV409) is a preclinical-stage drug candidate being developed by Disphar International (now Esperante Development, a member of the Sever Life Sciences Group) for ophthalmic indications. It is categorized within the company's "Full Development" pipeline, distinguishing it from their life cycle management and generic (aNDA) projects. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is part of a specialized portfolio focused on ophthalmology, which also includes candidates for glaucoma.
- Brand names
- Metivi
Beyond the preview
Go deeper on Metivi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metivi.